Get the Stockscreener App
2.69
0.55%
-0.05
After Hours:
2.69
Fortress Biotech Inc stock is traded at $2.69, with a volume of 456.97K.
It is down -0.55% in the last 24 hours and up +16.95% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See More
Previous Close:
$2.74
Open:
$2.8
24h Volume:
456.97K
Relative Volume:
0.67
Market Cap:
$89.36M
Revenue:
$66.16M
Net Income/Loss:
$128.94M
P/E Ratio:
0.8453
EPS:
3.1823
Net Cash Flow:
$152.08M
1W Performance:
+7.71%
1M Performance:
+16.95%
6M Performance:
-1.27%
1Y Performance:
+53.09%
1-Day Range:
$2.665
$2.835
1-Week Range:
$2.565
$2.86
52-Week Range:
$1.70
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.69 | 91.02M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelChaikin Flow - Newser
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
Fortress Biotech (FBIO) Q4 2025 Results Miss Estimates — EPS $-0.01 vs $0.11Consensus Beat Rate - Newser
Fortress Biotech (FBIO) Q4 2025 Earnings: Miss Sparks ConcernGAAP Earnings Report - Newser
Fortress Biotech (FBIO) Q4 2025 Miss: What Went WrongGuidance Downgrade Alert - Newser
Journey Medical CEO to join online talk at A.G.P. health event - Stock Titan
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference - Sahm
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Why Fortress Biotech (FBIO) Just Surged +5.81% — Key Levels Ahead 2026-05-18Factor Timing - Newser
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalys - AD HOC NEWS
Fortress Biotech Inc at Planet MicroCap Showcase Virtual Investor Conference 2020 Transcript - GuruFocus
Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake - Stock Titan
FBIOP | Fortress Biotech, Inc. 9.375% Insider Trading - Quiver Quantitative
Fortress Biotech (FBIO) Q1: EPS $2.82 Beats Est. -$0.22; Revenue - GuruFocus
Fortress Biotech Q1 2026 Earnings Call Transcript - MarketBeat
Fortress Biotech: Q1 Earnings Snapshot - marketscreener.com
Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82— 10-Q Summary - TradingView
Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M - TradingView
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale - Stock Titan
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - Yahoo Finance
Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum - AD HOC NEWS
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - marketscreener.com
(FBIOP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TradingKey - TradingKey
MSN Money - MSN
Fortress Biotech Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Earnings Preview: FBIO to Report Financial Results Post-market on May 13 - Moomoo
Journey Medical to discuss quarterly results and corporate update May 13 - Stock Titan
Mustang Bio (NASDAQ: MBIO) reports Q1 loss, limited cash and Nasdaq bid-price risk - Stock Titan
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - marketscreener.com
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Executive pay, ownership and auditor up for vote at Fortress Biotech (NASDAQ: FBIO) - Stock Titan
What Is Driving Performance | Fortress Biotech posts 108.9% negative EPS miss vs estimatesWall Street Picks - Newser
Why Is Fortress Biotech Stock Falling Today? - MSN
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Fortress (FBIOP) Market Conditions | Fortress Biotech pref posts 108.9% steep EPS missInvestor Call - Cổng thông tin điện tử tỉnh Lào Cai
Fortress (FBIOP) Investment Case | Q4 2025: Earnings Fall ShortCrowd Trend Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):